Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone drug class undergoing clinical trials prior to a possible NDA (New Drug Application) submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.

CAS：123447-62-1
中文别名：6-氟-1-甲基-7-[4-(5-甲基-2-氧代-1,3-二氧杂环戊烯-4-基)-甲基-1-哌啶基]-4-氧代-4H-[1,3]硫氮杂环丁烷并[3,2-a]喹啉-3-羧酸;6-氟-1-甲基-7-{4-(5-甲基-2-氧代-1,3-二噁茂烷-4-基)-甲基-1-哌啶基}-4-氧代-1H,4H-[1,3]噻啶并[3,2-A]-3-喹啉羧酸;
英文别名：Quisnon;Sword;nm441;SEA BUCKTHORN P.E;
分子式：C21H20FN3O6S
分子量：461.463
精确质量：461.106
Psa：134.43
Logp：2.6427

UNII：J42298IESW

外观与性状：黄色或略黄色粉末
密度：1.62 g/cm3
沸点：633.2ºC at 760 mmHg
闪点：336.8ºC
折射率：1.698
蒸汽压：1.77E-20mmHg at 25°C

用途
喹诺酮类抗生素。